PTN
PTN clinical trials: PALATIN TECHNOLOGIES INC
Every trial on ClinicalTrials.gov where PALATIN TECHNOLOGIES INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 12
- Trials linked
- 11
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
PTN on the catalyst calendar · PTN registry changes
- Primary completion Dec 8, 2023ActualPhase 2NCT04318145Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure SubjectsPalatin Technologies, Inc · Heart Failure With Preserved Ejection FractionTerminatedPTNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 5, 2025ActualPhase 2NCT06565611A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of ObesityPalatin Technologies, Inc · ObesityActive, not recruitingPTNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 10, 2025ActualPhase 2NCT05466890Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)Palatin Technologies, Inc · Ulcerative ColitisActive, not recruitingPTNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 26, 2024ActualPhase 2NCT05709444A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney DiseasePalatin Technologies, Inc · Kidney DiseaseCompletedPTNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 1, 2023ActualPhase 3NCT05201170A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry EyePalatin Technologies, Inc · Dry EyeCompletedPTNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2016ActualPhase 3NCT023330711. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire DisorderPalatin Technologies, Inc · Hypoactive Sexual Desire DisorderCompletedPTNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2016ActualPhase 3NCT023389602. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire DisorderPalatin Technologies, Inc · Hypoactive Sexual Desire DisorderCompletedPTNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredPhase 2NCT01304628Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate AsthmaPalatin Technologies, Inc · AsthmaWithdrawnPTNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2012ActualPhase 2NCT01382719Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire DisorderPalatin Technologies, Inc · Female Sexual Arousal DisorderCompletedPTNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2008ActualPhase 2NCT00686803Safety Study of Subcutaneously Administered PL-3994 in Subjects With Controlled HypertensionPalatin Technologies, Inc · HypertensionCompletedPTNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2007ActualPhase 2NCT00425256Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)Palatin Technologies, Inc · Sexual Arousal DisorderCompletedPTNLeadPFECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 5, 2020ActualPhase 2NCT04268069Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry EyeORA, Inc. · Dry Eye DiseaseCompletedPTNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 12 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner